ベキサロテン (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ベキサロテン" in Japanese language version.

refsWebsite

Global rank Japanese rank

12nih.gov

4^th place

24^th place

11doi.org

2^nd place

6^th place

2pmda.go.jp

6,690^th place

394^th place

2livedoor.jp

1,987^th place

140^th place

1aacrjournals.org

8,869^th place

low place

1ascopubs.org

low place

1medicines.org.uk

3,823^rd place

low place

1wikipedia.org

low place

1medscape.com

719^th place

3,311^th place

1sri.com

low place

1fda.gov

447^th place

1,043^rd place

1drugs.com

399^th place

1,603^rd place

1europa.eu

68^th place

425^th place

1nikkeibp.co.jp

1,415^th place

95^th place

1jaspo-oncology.org

low place

1medicalxpress.com

8,255^th place

low place

1medicalnewstoday.com

3,011^th place

8,599^th place

aacrjournals.org

clincancerres.aacrjournals.org

Dragnev, KH; Petty, WJ; Shah, SJ; Lewis, LD; Black, CC; Memoli, V; Nugent, WC; Hermann, T; Negro-Vilar, A; Rigas, JR; Dmitrovsky, E (2007). “A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer” (PDF). Clinical Cancer Research 13 (6): 1794–800. doi:10.1158/1078-0432.CCR-06-1836. PMID 17363535.

ascopubs.org

jco.ascopubs.org

Esteva, FJ; Glaspy, J; Baidas, S; Laufman, L; Hutchins, L; Dickler, M; Tripathy, D; Cohen, R; DeMichele, A; Yocum, RC; Osborne, CK; Hayes, DF; Hortobagyi, GN; Winer, E; Demetri, GD (March 2003). “Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer” (PDF). Journal of Clinical Oncology 21 (6): 999–1006. doi:10.1200/JCO.2003.05.068. PMID 12637463.

doi.org

Gniadecki, R; Assaf, C; Bagot, M; Dummer, R; Duvic, M; Knobler, R; Ranki, A; Schwandt, P; Whittaker, S (2007). “The optimal use of bexarotene in cutaneous T-cell lymphoma”. British Journal of Dermatology 157 (3): 433–40. doi:10.1111/j.1365-2133.2007.07975.x. PMID 17553039.
Dragnev, KH; Petty, WJ; Shah, SJ; Lewis, LD; Black, CC; Memoli, V; Nugent, WC; Hermann, T; Negro-Vilar, A; Rigas, JR; Dmitrovsky, E (2007). “A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer” (PDF). Clinical Cancer Research 13 (6): 1794–800. doi:10.1158/1078-0432.CCR-06-1836. PMID 17363535.
Esteva, FJ; Glaspy, J; Baidas, S; Laufman, L; Hutchins, L; Dickler, M; Tripathy, D; Cohen, R; DeMichele, A; Yocum, RC; Osborne, CK; Hayes, DF; Hortobagyi, GN; Winer, E; Demetri, GD (March 2003). “Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer” (PDF). Journal of Clinical Oncology 21 (6): 999–1006. doi:10.1200/JCO.2003.05.068. PMID 12637463.
Rowe, A (February 1997). “Retinoid X receptors”. The International Journal of Biochemistry & Cell Biology 29 (2): 275–278. doi:10.1016/S1357-2725(96)00101-X. PMID 9147128.
Dawson, M. I.; Xia, Z. (2012). “The retinoid X receptors and their ligands”. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1821 (1): 21–56. doi:10.1016/j.bbalip.2011.09.014. PMC 4097889. PMID 22020178.
Qu, L; Tang, X (January 2010). “Bexarotene: a promising anticancer agent”. Cancer Chemotherapy Pharmacology 65 (2): 201–205. doi:10.1007/s00280-009-1140-4. PMID 19777233.
Cramer, P. E.; Cirrito, J. R.; Wesson, D. W.; Lee, C. Y. D.; Karlo, J. C.; Zinn, A. E.; Casali, B. T.; Restivo, J. L. et al. (2012). “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”. Science 335 (6075): 1503–1506. doi:10.1126/science.1217697. PMC 3651582. PMID 22323736.
Fitz, N. F.; Cronican, A. A.; Lefterov, I.; Koldamova, R. (2013). “Comment on "ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models"”. Science 340 (6135): 924. doi:10.1126/science.1235809.
Price, A. R.; Xu, G.; Siemienski, Z. B.; Smithson, L. A.; Borchelt, D. R.; Golde, T. E.; Felsenstein, K. M. (2013). “Comment on "ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models"”. Science 340 (6135): 924. doi:10.1126/science.1234089.
Tesseur, I.; Lo, A. C.; Roberfroid, A.; Dietvorst, S.; Van Broeck, B.; Borgers, M.; Gijsen, H.; Moechars, D. et al. (2013). “Comment on "ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models"”. Science 340 (6135): 924. doi:10.1126/science.1233937.
Veeraraghavalu, K.; Zhang, C.; Miller, S.; Hefendehl, J. K.; Rajapaksha, T. W.; Ulrich, J.; Jucker, M.; Holtzman, D. M. et al. (2013). “Comment on "ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models"”. Science 340 (6135): 924. doi:10.1126/science.1235505.

drugs.com

“Bexarotene”. Drugs.com. 12 January 2014閲覧。

europa.eu

ema.europa.eu

“Targretin : EPAR - Product Information” (PDF). European Medicines Agency. Eisai Ltd (3 April 2013). 12 January 2014閲覧。

fda.gov

accessdata.fda.gov

“Drug Approval Package: Targretin (Bexarotene) NDA# 21-055”. FDA. 2016年4月3日閲覧。

jaspo-oncology.org

“ベキサロテン製剤の使用にあたっての留意事項について”. 日本臨床腫瘍薬学会. 2016年4月3日閲覧。

livedoor.jp

blog.livedoor.jp

“アルツハイマー病特効薬の開発2” (2012年2月11日). 2016年4月3日閲覧。
“癌治療薬ベキサロテンは本当にアルツハイマー病に有効か？” (2013年5月24日). 2016年4月3日閲覧。

medicalnewstoday.com

“Anti-Cancer Drug Reverses Alzheimer's Disease In Mice”. Medical News Today (25 May 2013). 2016年4月3日閲覧。

medicalxpress.com

MedicalXpress (9 February 2012). “FDA-approved drug rapidly clears amyloid from the brain, reverses Alzheimer's symptoms in mice” 14 February 2012閲覧。

medicines.org.uk

“Targretin Capsules - Summary of Product Characteristics”. electronic Medicines Compendium. Eisai Ltd (4 April 2013). 14 January 2014閲覧。

medscape.com

reference.medscape.com

“Targretin (bexarotene) dosing, indications, interactions, adverse effects, and more”. Medscape Reference. WebMD. 31 January 2014閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

Gniadecki, R; Assaf, C; Bagot, M; Dummer, R; Duvic, M; Knobler, R; Ranki, A; Schwandt, P; Whittaker, S (2007). “The optimal use of bexarotene in cutaneous T-cell lymphoma”. British Journal of Dermatology 157 (3): 433–40. doi:10.1111/j.1365-2133.2007.07975.x. PMID 17553039.
Dragnev, KH; Petty, WJ; Shah, SJ; Lewis, LD; Black, CC; Memoli, V; Nugent, WC; Hermann, T; Negro-Vilar, A; Rigas, JR; Dmitrovsky, E (2007). “A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer” (PDF). Clinical Cancer Research 13 (6): 1794–800. doi:10.1158/1078-0432.CCR-06-1836. PMID 17363535.
Esteva, FJ; Glaspy, J; Baidas, S; Laufman, L; Hutchins, L; Dickler, M; Tripathy, D; Cohen, R; DeMichele, A; Yocum, RC; Osborne, CK; Hayes, DF; Hortobagyi, GN; Winer, E; Demetri, GD (March 2003). “Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer” (PDF). Journal of Clinical Oncology 21 (6): 999–1006. doi:10.1200/JCO.2003.05.068. PMID 12637463.
Rowe, A (February 1997). “Retinoid X receptors”. The International Journal of Biochemistry & Cell Biology 29 (2): 275–278. doi:10.1016/S1357-2725(96)00101-X. PMID 9147128.
Dawson, M. I.; Xia, Z. (2012). “The retinoid X receptors and their ligands”. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1821 (1): 21–56. doi:10.1016/j.bbalip.2011.09.014. PMC 4097889. PMID 22020178.
Qu, L; Tang, X (January 2010). “Bexarotene: a promising anticancer agent”. Cancer Chemotherapy Pharmacology 65 (2): 201–205. doi:10.1007/s00280-009-1140-4. PMID 19777233.
Cramer, P. E.; Cirrito, J. R.; Wesson, D. W.; Lee, C. Y. D.; Karlo, J. C.; Zinn, A. E.; Casali, B. T.; Restivo, J. L. et al. (2012). “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”. Science 335 (6075): 1503–1506. doi:10.1126/science.1217697. PMC 3651582. PMID 22323736.

ncbi.nlm.nih.gov

Dawson, M. I.; Xia, Z. (2012). “The retinoid X receptors and their ligands”. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1821 (1): 21–56. doi:10.1016/j.bbalip.2011.09.014. PMC 4097889. PMID 22020178.
Cramer, P. E.; Cirrito, J. R.; Wesson, D. W.; Lee, C. Y. D.; Karlo, J. C.; Zinn, A. E.; Casali, B. T.; Restivo, J. L. et al. (2012). “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”. Science 335 (6075): 1503–1506. doi:10.1126/science.1217697. PMC 3651582. PMID 22323736.

pmc.ncbi.nlm.nih.gov

Dawson, M. I.; Xia, Z. (2012). “The retinoid X receptors and their ligands”. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1821 (1): 21–56. doi:10.1016/j.bbalip.2011.09.014. PMC 4097889. PMID 22020178.
Cramer, P. E.; Cirrito, J. R.; Wesson, D. W.; Lee, C. Y. D.; Karlo, J. C.; Zinn, A. E.; Casali, B. T.; Restivo, J. L. et al. (2012). “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”. Science 335 (6075): 1503–1506. doi:10.1126/science.1217697. PMC 3651582. PMID 22323736.

dailymed.nlm.nih.gov

“TARGRETIN (BEXAROTENE) CAPSULE [CARDINAL HEALTH]”. DailyMed. Cardinal Health (March 2006). 12 January 2014閲覧。

nikkeibp.co.jp

medical.nikkeibp.co.jp

“2成分目の皮膚T細胞性リンパ腫の経口治療薬”. 日経メディカル (2016年2月12日). 2016年4月3日閲覧。

pmda.go.jp

info.pmda.go.jp

“タルグレチンカプセル75mg 添付文書” (2016年1月). 2016年7月2日閲覧。
“タルグレチンカプセル75mg インタビューフォーム”. ミノファーゲン製薬 (2016年1月). 2016年4月3日閲覧。

sri.com

“Lymphoma Treatment: Targretin (bexarotene)”. Timeline of Innovation. SRI International. 2013年9月20日閲覧。

wikipedia.org

en.wikipedia.org

Brunton, L; Chabner, B; Knollman, B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics（英語版） (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8